Adicet Bio Inc (ACET)

Currency in USD
8.510
+0.060(+0.71%)
Closed·
8.685+0.175(+2.06%)
·
ACET is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.3308.880
52 wk Range
6.01017.438
Key Statistics
Prev. Close
8.51
Open
8.61
Day's Range
8.33-8.88
52 wk Range
6.01-17.438
Volume
106.47K
Average Volume (3m)
143.6K
1-Year Change
-11.7659%
Book Value / Share
15.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.833
Upside
+309.32%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Adicet Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.833
(+309.32% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Buy19.00+123.27%-New Coverage04/05/2026
Jones Trading
Buy20.00+135.02%-New Coverage06/04/2026
H.C. Wainwright
Buy27.00+217.27%50.00Maintain23/03/2026
Guggenheim
Buy100.00+1,075.09%128.00Maintain13/03/2026
H.C. Wainwright
Buy50.00+487.54%9.00Maintain21/01/2026

Adicet Bio Inc SWOT Analysis


Gamma-Delta Pionee
Adicet Bio leads in engineered gamma-delta T cell therapies, with promising candidates for lupus nephritis and renal cell carcinoma in Phase 1 trials
Financial Fortitude
Strong cash position of $150.4M supports ongoing clinical trials, though rapid cash burn rate poses future funding challenges
Expanding Horizons
Explore Adicet's ambitious pipeline expansion into multiple autoimmune conditions, showcasing the versatility of its innovative platform
Market Valuation
With analyst price targets ranging from $4 to $8 per share, Adicet's current trading price of $0.69 presents a potential asymmetric upside opportunity
Read full SWOT analysis

Earnings

Latest Release
05/03/2026
EPS / Forecast
-2.84 / -0.19
Revenue / Forecast
-- / 2.5M
EPS Revisions
Last 90 days

Compare ACET to Peers and Sector

Metrics to compare
ACET
Peers
Sector
Relationship
P/E Ratio
−0.8x−3.3x−0.5x
PEG Ratio
−0.04−0.180.00
Price/Book
0.6x2.5x2.6x
Price / LTM Sales
-6.0x3.2x
Upside (Analyst Target)
166.3%257.5%47.8%
Fair Value Upside
Unlock11.8%5.9%Unlock

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.17M10.87%9.88M
Other Institutional Investors
7.63M71.02%64.51M
Public Companies & Retail Investors
1.95M18.10%16.44M
Total
10.75M100.00%90.83M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Healthcare Fund, L.P.11.00%1,182,6249,993
RA Capital Management, L.P.11.00%1,182,6249,993

People Also Watch

4.150
CABA
+8.36%
2.87
REPL
-5.28%
42.660
KOD
+0.95%

FAQ

What Is the Adicet Bio (NASDAQ: ACET) Share Price Today?

The Adicet Bio stock price today is 8.510 USD.

What Stock Exchange Does Adicet Bio (ACET) Trade On?

Adicet Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Adicet Bio?

The stock symbol (also called a 'ticker') for Adicet Bio is "ACET."

What Is the Current Adicet Bio Market Capitalisation?

As of today, Adicet Bio (NASDAQ: ACET) market cap is 91.480M USD.

What Is Adicet Bio's (ACET) Earnings Per Share (TTM)?

The Adicet Bio EPS is currently -16.949 (Trailing Twelve Months).

When Is the Next Adicet Bio Earnings Date?

Adicet Bio's next earnings report will be released on 05/03/2026.

Is ACET a Buy or Sell From a Technical Analyst Perspective?

Based on today's Adicet Bio moving averages and other technical indicators, the daily buy/sell signal for ACET stock is Strong Buy.

How Many Times Has Adicet Bio Stock Split?

Adicet Bio has split 2 times. (See the ACET stock split history page for full effective split date and price information.)

How Many Employees Does Adicet Bio Have?

Adicet Bio has 102 employees, based on their latest Companies House report.

What is the current trading status of Adicet Bio (NASDAQ: ACET)?

As of 06/05/2026, Adicet Bio (ACET) is trading at a share price of 8.510 USD, with a previous close of 8.510 USD. The stock has fluctuated within a day range of 8.330 USD to 8.880 USD, while its 52-week range spans from 6.010 USD to 17.438 USD.

What Is Adicet Bio (ACET) Price Target According to Analysts?

The average 12-month price target for Adicet Bio is 34.833 USD, with a high estimate of 100 USD and a low estimate of 18 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +309.32% Upside potential.

What Is the ACET Premarket Price?

ACET's last pre-market stock price is 8.685 USD. The pre-market share volume is 20.000, and the stock has decreased by 0.175, or 2.060%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.